Ramzi Mani, Dehghani Mehdi, Haghighat Shirin, Nejad Hourvash Haghighi
From the Hematology Research Center, Department of Hematology, Medical Oncology, and Stem Cell Transplantation, Shiraz University of Medical Sciences, Shiraz, Iran.
Exp Clin Transplant. 2016 Dec;14(6):688-690. doi: 10.6002/ect.2014.0165. Epub 2015 Jul 2.
Glanzmann thrombasthenia is an inherited auto-somal recessive disorder characterized by normal platelet count but lack of platelet aggregation due to absence of platelet glycoprotein IIb/IIIa. The disease usually is associated with mild bleeding, but severe fatal hemorrhage may occur. Allogeneic stem cell transplant is the only curative method of treatment. A literature search showed 18 previously reported cases of Glanzmann thrombasthenia treated with allogeneic hematopoietic stem cell transplant. We report an 18-year-old woman with severe Glanzmann thrombasthenia who was treated with allogeneic hematopoietic stem cell transplant from her sister. After 24-month follow-up, the patient was well, had no bleeding tendency, and had mild chronic skin graft-versus-host disease.
血小板无力症是一种常染色体隐性遗传性疾病,其特征为血小板计数正常,但因缺乏血小板糖蛋白IIb/IIIa而导致血小板聚集功能缺失。该疾病通常与轻度出血相关,但也可能发生严重的致命性出血。异基因干细胞移植是唯一的治愈性治疗方法。一项文献检索显示,此前有18例血小板无力症患者接受了异基因造血干细胞移植的报道。我们报告了一名18岁患有严重血小板无力症的女性患者,她接受了来自其姐姐的异基因造血干细胞移植。经过24个月的随访,患者情况良好,无出血倾向,且患有轻度慢性移植物抗宿主病。